BMRA

Biomerica Inc. (BMRA) | Rumor.io

Biomerica

BMRA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,730

Bullish sentiment (50-day avg)88%

Price to earnings ratio0

Market capitalization11M

Earnings per share-1.3

Dividend yield (TTM)—

Revenue (annual)4.5M

Net income (annual)-3.8M

Social

What share of all stock conversation is about BMRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 27

Biomerica, Inc. (BMRA) announced a $2.23 million private placement at $1.60 per share, with B. Riley as the exclusive financial advisor.
The financing will provide approximately $2.23 million in gross proceeds to Biomerica, and the company's CEO and all members of the Board of Directors participated in the financing.
B. Riley will now be exclusive adviser on a strategic review, which may include sale, merger, partnership, or spin-off options, and the company will provide updates on cash runway and inFoods milestones.

Generated by AI

Sentiment

Of the messages about BMRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +14.29	78.99% +1.33
Bearish	—	0%	0% -14.29	21.01% -1.33

Bullish· Sep 4

Biomerica, Inc. ($BMRA) has significant potential for growth, with some investors predicting it will reach $3 or even $4.
The company's news is highly regarded, with one investor stating that the news is "too good" for the stock to remain under $3.
Biomerica, Inc. ($BMRA) could be the next "DD ticker" (a popular stock among day traders), with one investor suggesting it could eventually reach $4 or more.

Bearish· Aug 14

$BMRA has struggled to hold its ground, with one user noting it can't even hold $4 despite significant volume.
The stock has been heavily dilutive, with one user suggesting this is the reason it can't move on positive news.
$BMRA has a history of failing to hold gains, with one user noting they've lost 92% in 5 years and another user suggesting it's due to massive dilution.

Generated by AI

Topics

Of the messages about BMRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	78.89%
Analysts	—	—	0%	1.11%
Technical Analysis	—	—	0%	20%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Oct 16

Biomerica, Inc. (BMRA) has entered into a marketing services agreement with Henry Schein to promote its inFoods IBS test in the U.S.
The agreement aims to leverage Henry Schein's extensive network of medical field sales and telesales representatives to increase awareness and adoption of the test.
Henry Schein is a Fortune 500 company with $12 billion in annual sales and a strong presence in the medical and dental products distribution market.

Technical Analysis· Jan 16

Biomerica, Inc. ($BMRA) may be due for a price increase if it breaks above $1.30-$1.35.
A potential area of resistance for $BMRA is around $1.20, which the asset needs to break through for further growth.
The asset's recent price action has been characterized by a potential retrace and a possible parabolic move, with some traders expecting a bounce over $0.85-$0.90.

Generated by AI

Community

Of the messages about BMRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	8.33%	34.89%
Newcomers	—	100%	91.67%	65.11%

Regulars· Aug 27

Biomerica, Inc. has secured $2.23 million in financing through a private placement of 1.39 million shares at $1.60 per share, with no warrants or discount.
B. Riley will serve as the exclusive adviser on a strategic review of Biomerica, which may include a sale, merger, partnership, or spin-off, but no specific outcome has been announced.
The recent private financing is expected to provide a solid foundation for Biomerica's future growth, and the company's CEO and full board of directors participated in the financing, indicating a strong commitment to the company's success.

Newcomers· Aug 27

Biomerica, Inc. ($BMRA) has entered into a private placement agreement with institutional and individual investors, raising $2.23 million at $1.60 per share.
The company's CEO, Irani Zackary S., has purchased 31,250 shares at $1.60 per share, increasing their position by +15%.
Biomerica has engaged B. Riley as its exclusive financial advisor, and insiders have been actively buying shares, including a recent purchase by director David Moatazedi.

Generated by AI

News

Also Discussed

Investors talking about BMRA also mention

#	Name	Attention
1	PBLA - Panbela Therapeutics, Inc.	——
2	Cuentas Inc.CUEN	0%+0
3	Aytu BioPharma, Inc.AYTU	0%0
4	Nemaura Medical Inc.NMRD	0%new
5	iShares Morningstar Mid-Cap Growth ETFIMCG	0%new
6	TCTM - TCTM Kids IT Education Inc.	——
7	CytoMed Therapeutics Ltd.GDTC	0%0
8	Akso Health Group ADRAHG	0%0
9	RPHM - Reneo Pharmaceuticals, Inc.	——
10	Intelligent Protection Management Corp.IPM	0%0

Biomerica Inc.

Healthcare
Medical Devices

Biomerica Inc. is a biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products. The company’s portfolio centers on in-vitro diagnostic solutions used in point-of-care settings, physicians’ offices, and hospital and clinical laboratories. Its products address a range of medical conditions, with emphasis on gastrointestinal and inflammatory diseases, food intolerances, diabetes, and other diagnostic applications. Biomerica Inc. also serves clinical laboratory, physician office, home testing, and over-the-counter channels, supporting early detection and treatment decisions across multiple healthcare environments. Based in Irvine, California, the company operates as a specialized healthcare provider with a market presence in both diagnostic testing and therapeutic product development.

Website

Location

17571 Von Karman Avenue

Irvine, CA, 92614

United States

Social

What share of all stock conversation is about BMRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 27

Biomerica, Inc. (BMRA) announced a $2.23 million private placement at $1.60 per share, with B. Riley as the exclusive financial advisor.
The financing will provide approximately $2.23 million in gross proceeds to Biomerica, and the company's CEO and all members of the Board of Directors participated in the financing.
B. Riley will now be exclusive adviser on a strategic review, which may include sale, merger, partnership, or spin-off options, and the company will provide updates on cash runway and inFoods milestones.

Generated by AI

Sentiment

Of the messages about BMRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +14.29	78.99% +1.33
Bearish	—	0%	0% -14.29	21.01% -1.33

Bullish· Sep 4

Biomerica, Inc. ($BMRA) has significant potential for growth, with some investors predicting it will reach $3 or even $4.
The company's news is highly regarded, with one investor stating that the news is "too good" for the stock to remain under $3.
Biomerica, Inc. ($BMRA) could be the next "DD ticker" (a popular stock among day traders), with one investor suggesting it could eventually reach $4 or more.

Bearish· Aug 14

$BMRA has struggled to hold its ground, with one user noting it can't even hold $4 despite significant volume.
The stock has been heavily dilutive, with one user suggesting this is the reason it can't move on positive news.
$BMRA has a history of failing to hold gains, with one user noting they've lost 92% in 5 years and another user suggesting it's due to massive dilution.

Generated by AI

Topics

Of the messages about BMRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	78.89%
Analysts	—	—	0%	1.11%
Technical Analysis	—	—	0%	20%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Oct 16

Biomerica, Inc. (BMRA) has entered into a marketing services agreement with Henry Schein to promote its inFoods IBS test in the U.S.
The agreement aims to leverage Henry Schein's extensive network of medical field sales and telesales representatives to increase awareness and adoption of the test.
Henry Schein is a Fortune 500 company with $12 billion in annual sales and a strong presence in the medical and dental products distribution market.

Technical Analysis· Jan 16

Biomerica, Inc. ($BMRA) may be due for a price increase if it breaks above $1.30-$1.35.
A potential area of resistance for $BMRA is around $1.20, which the asset needs to break through for further growth.
The asset's recent price action has been characterized by a potential retrace and a possible parabolic move, with some traders expecting a bounce over $0.85-$0.90.

Generated by AI

Community

Of the messages about BMRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	8.33%	34.89%
Newcomers	—	100%	91.67%	65.11%

Regulars· Aug 27

Biomerica, Inc. has secured $2.23 million in financing through a private placement of 1.39 million shares at $1.60 per share, with no warrants or discount.
B. Riley will serve as the exclusive adviser on a strategic review of Biomerica, which may include a sale, merger, partnership, or spin-off, but no specific outcome has been announced.
The recent private financing is expected to provide a solid foundation for Biomerica's future growth, and the company's CEO and full board of directors participated in the financing, indicating a strong commitment to the company's success.

Newcomers· Aug 27

Biomerica, Inc. ($BMRA) has entered into a private placement agreement with institutional and individual investors, raising $2.23 million at $1.60 per share.
The company's CEO, Irani Zackary S., has purchased 31,250 shares at $1.60 per share, increasing their position by +15%.
Biomerica has engaged B. Riley as its exclusive financial advisor, and insiders have been actively buying shares, including a recent purchase by director David Moatazedi.

Generated by AI

Biomerica

Social

Aug 27

Bullish· Sep 4

Bearish· Aug 14

Announcements· Oct 16

Technical Analysis· Jan 16

Regulars· Aug 27

Newcomers· Aug 27

Biomerica director Gary M. Huff acquires $50,000 in BMRA stock

Biomerica director Gary Huff buys $50,000 in common stock

Biomerica raises $2.23 million in private placement at $1.60

Also Discussed

Biomerica Inc.

Company Information

Location

Biomerica director Gary M. Huff acquires $50,000 in BMRA stock

Biomerica director Gary Huff buys $50,000 in common stock

Biomerica raises $2.23 million in private placement at $1.60

Also Discussed

Social

Aug 27

Bullish· Sep 4

Bearish· Aug 14

Announcements· Oct 16

Technical Analysis· Jan 16

Regulars· Aug 27

Newcomers· Aug 27